Nanexa AB (publ) (STO:NANEXA)

Market Cap	706.11M
Revenue (ttm)	31.92M
Net Income (ttm)	-39.06M
Shares Out	158.68M
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,865,494
Average Volume	2,281,870
Open	4.920
Previous Close	4.920
Day's Range	4.450 - 5.000
52-Week Range	0.701 - 5.000
Beta	2.17
RSI	75.31
Earnings Date	Feb 19, 2026

About Nanexa AB

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, rest of Europe, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a depot drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 13
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: NANEXA

Financial Performance

In 2024, Nanexa AB's revenue was 46.69 million, a decrease of -21.07% compared to the previous year's 59.16 million. Losses were -24.91 million, -67.40% less than in 2023.